PERSEUS Supports D-VRd Followed by DR Maintenance as New SOC in MM
Paula Rodriguez-Otero, MD, PhD, discusses the promising results from the phase 3 PERSEUS trial in patients with newly diagnosed, transplant-eligible multiple myeloma.
Paula Rodriguez-Otero, MD, PhD, University Clinic of Navarra, Pamplona, Spain, discusses the promising results from the phase 3 PERSEUS trial (NCT03710603), a randomized, interventional, open-label, study comparing subcutaneous daratumumab (Darzalex) followed by autologous stem cell transplant (ASCT) and daratumumab, bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) consolidation and daratumumab/lenalidomide maintenance in patients with newly diagnosed, transplant-eligible multiple myeloma.
According to Otero, this regimen significantly prolonged the rates of progression-free survival (PFS) in this patient population. At a median follow-up of 47.5 months, the 4-year PFS rate observed among patients treated with D-VRd was 84.3% vs 67.7% with VRd. This led to a 58% reduction in the risk of disease progression or death with the addition of the CD38 monoclonal antibody (HR, 0.42; 95% CI, 0.30-0.59; P <.0001). Further, the overall rate of complete response or better (≥CR) was 87.9% with D-VRd vs 70.1% with VRd (P <.0001).
These findings will likely change the standard of care for the treatment of patients with newly diagnosed multiple myeloma.
Transcription:
0:09 | This is a late breaker and also the 1 of the most relevant abstracts that was presented [at the 2023 ASH Annual Meeting] because this probably [and] clearly will change the standard of care for treatment of [patients with] newly diagnosed multiple myeloma that are candidates for transplant. The results presented by Dr. Sonneveld were very impressive, mostly because of the high rates of minimal residual disease in the D-VRd treatment arm.
0:43 | [This also led] to an improvement in PFS in these patients, and these are probably 1 of the higher rates of MRD negativity shown in the setting of the newly diagnosed frontline and transplant eligible candidates. I think that this is a very important abstract, a very important paper, and a very important treatment to give to all of our [patients with] newly diagnosed transplant eligible myeloma.
REFERENCE
Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Phase 3 randomized study of daratumumab + bortezomib, lenalidomide, and dexamethasone (VRd) versus VRd alone in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: primary results of the PERSEUS trial. Blood. 2023;142(suppl 2):LBA1. doi:10.1182/blood-2023.191911
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
